In the present study, the serum Lysyl Oxidase level was higher in ovarian cancer patients than the control subjects and advanced stage (FIGO III and IV and TNM 3) showed significantly raised Lysyl oxidase levels as compared to early stages (FIGO I and II, TNM 1 and 2), suggesting its role in the diagnosis and prognosis of ovarian cancer patients. This evidence concerns the gene LOX and ovarian carcinoma.